Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
Randomized study of PRT054021 40 mg and 15 mg bid vs. enoxaparin 30 mg q12h for the
prophylaxis of venous thromboembolic events after unilateral knee replacement surgery.